Emactuzumab
- Product NameEmactuzumab
- CAS1448221-67-7
- CBNumberCB98080911
- MW0
- MOL FileMol file
- MSDS FileSDS
Chemical Properties
| form | Liquid |
| color | Colorless to light yellow |
| FDA UNII | 6FY6EI1X8R |
| NCI Drug Dictionary | emactuzumab |
Emactuzumab Price
| Product number | Packaging | Price | Product description | Buy |
|---|---|---|---|---|
| ChemScene CS-0612557 | 1mg | $379 | Emactuzumab 97.60% |
Buy |
| ChemScene CS-0612557 | 5mg | $975 | Emactuzumab 97.60% |
Buy |
| ChemScene CS-0612557 | 10mg | $1517 | Emactuzumab 97.60% |
Buy |
| Biorbyt Ltd orb1290207 | 100μg | $280 | Emactuzumab >95% |
Buy |
| Biorbyt Ltd orb1290207 | 1mg | $820 | Emactuzumab >95% |
Buy |
Emactuzumab Chemical Properties,Usage,Production
Uses
Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) [1][2].in vivo
Emactuzumab(RG 7155) (i.v.; 0.1, 1, 10, 30 and 100 mg/kg; once) increases CSF-1 concentration in nonhuman primates’ peripheral blood[2].
RG7155 (i.v.; 0, 30, and 100 mg/kg; once weekly; for 2 weeks) depletes CSF-1R+CD163+ macrophages in vivo[2].
| Animal Model: | cynomolgus monkeys Macaca fascicularis[2] |
| Dosage: | 0.1, 1, 10, 30 and 100 mg/kg (male cynomolgus monkeys) 0, 30, and 100 mg/kg (male and female cynomolgus) |
| Administration: | i.v., once (male cynomolgus monkeys) i.v., once weekly, for 2 weeks(male and female cynomolgus) |
| Result: | Increased CSF-1 concentration in serum. Efficiently reduced CSF-1R and CD68+163+ macrophages in the liver (Kupffer cells) and colon of cynomologus monkeys. |
References
[1] Philippe A Cassier, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015 Aug;16(8):949-56. DOI:10.1016/S1470-2045(15)00132-1[2] Carola H Ries, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014 Jun 16;25(6):846-59. DOI:10.1016/j.ccr.2014.05.016
Preparation Products And Raw materials
Emactuzumab Suppliers
Global(22)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| 18916372613 | yanzihan@shyuanye.com | China | 87240 | 60 | |
| +1-781-999-5354; +1-00000000000 |
marketing@targetmol.com | United States | 32431 | 58 | |
| 15817493340 | 981810490@qq.com | China | 1577 | 58 | |
| 027-65317797 15926423062 |
422450190@qq.com | China | 10300 | 58 | |
| 010-60605840 | psaitong@jm-bio.com | China | 27756 | 58 | |
| 4008200310 15002144251 |
marketing@tsbiochem.com | China | 24951 | 58 | |
| 027-65279366 18108604356 |
products@biolabreagent.com | China | 9864 | 58 | |
| 13720134139 086-15871494362 13720134139 |
orders@jknbiochem.com | China | 7284 | 58 | |
| 021-65675885 18964387627 |
customer_service@efebio.com | China | 11963 | 58 | |
| 027-027-16602739303 16602739303 |
673003916@qq.com | China | 4658 | 58 |
View Latest Prices from Emactuzumab manufacturers
1448221-67-7, EmactuzumabRelated Search
PROMPT×
PROMPT
The WhatsApp is temporarily not supported in mainland China
The WhatsApp is temporarily not supported in mainland China
Cancel
Determine